Tralokinumab vs. Dupilumab in Atopic Dermatitis: Comparative Effectiveness Study

doi:N/A

eISSN: None / ISSN: 1673-5269

Chinese Journal of Cancer Prevention & Treatment

2026, Volume: 33, Issue 5 : 5-6

Research Article

Tralokinumab vs. Dupilumab in Atopic Dermatitis: Comparative Effectiveness Study

Balasubramanian K

Venkatesan R, Annamalai P

Received

April 20, 2026

Accepted

May 2, 2026

Published

May 25, 2026

Abstract

Background: Direct comparison of IL-13 vs. IL-4/IL-13 antagonism in atopic dermatitis informs treatment selection. Methods: Indirect treatment comparison and real-world analysis of 820 patients with moderate-severe AD on tralokinumab vs. dupilumab. Primary outcome: EASI-75 at 16 weeks. Results: EASI-75: tralokinumab 58.9% vs. dupilumab 64.3% (p=0.08). Conjunctivitis incidence significantly lower with tralokinumab (2.1% vs. 9.8%, p<0.001). Patient preference favored tralokinumab due to fewer ocular side effects. Conclusion: Tralokinumab offers comparable efficacy to dupilumab with significantly lower conjunctivitis risk, facilitating individualized therapy selection.

Keywords

Tralokinumab

Dupilumab

Atopic dermatitis

EASI-75

Conjunctivitis

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.

ISSN: 1673-5269 open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.

Recommended Articles

circRNA-NDUFA10 inhibits angiogenesis of bladder cancer; circRNA-NDUFA10抑制膀胱癌血管新生的机制研究

L. Ai,

Z.-X. Feng,

Y.-N. Yin,

M. Su,

Z.-H. Li

1668-1675

Value of multi-parameter quantitative analysis of spectral CT in differentiating pathological types of lung cancer; 能谱CT多参数定量分析鉴别肺癌病理类型的应用价值

Z.-S. Cheng,

S.-L. Li,

W.-W. Li,